The PRX Gene Dejerine-Sottas Disease Genetic Test is a specialized diagnostic tool used to identify mutations in the PRX gene, which are associated with Dejerine-Sottas Disease (DSD), also known as Hereditary Motor and Sensory Neuropathy Type III. DSD is a rare, inherited neurological disorder characterized by progressive muscle weakness and sensory loss, primarily affecting the peripheral nervous system. Early detection through genetic testing can be crucial for managing symptoms, planning treatment strategies, and providing genetic counseling for affected families.
Conducted at DNA Labs UAE, this genetic test offers a comprehensive analysis of the PRX gene to detect mutations that may lead to the development of Dejerine-Sottas Disease. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed using advanced genetic sequencing technologies to identify any genetic abnormalities.
The cost of the PRX Gene Dejerine-Sottas Disease Genetic Test is 4400 AED. While the price may seem high, the value of the information gained can be significant for patients and their families, providing insights into the genetic basis of the condition, enabling early intervention, and facilitating informed decisions about care and management. It is advisable for individuals considering this test to consult with a healthcare professional or a genetic counselor to understand the implications of the results and the next steps in the context of their personal and family health history.
The ITM2B Gene Dementia Familial British Type Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, aimed at identifying mutations in the ITM2B gene, which are linked to the development of Familial British Dementia (FBD). This rare form of dementia is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. Symptoms typically emerge in mid-adulthood, leading to progressive cognitive decline, neurological problems, and movement disorders.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed to detect specific genetic alterations in the ITM2B gene that are known to cause FBD. This genetic test is crucial for families with a history of FBD, as it can provide a definitive diagnosis for affected individuals, inform at-risk family members of their genetic status, and guide clinical management and surveillance for the condition.
Priced at 4400 AED, the ITM2B Gene Dementia Familial British Type Genetic Test at DNA Labs UAE represents a significant step forward in the personalized diagnosis and management of this rare dementia, offering hope and clarity for affected individuals and their families.
The ITM2B Gene Dementia Familial Danish Type Genetic Test is a specialized diagnostic procedure designed to detect mutations in the ITM2B gene, which are associated with Familial Danish Dementia (FDD). This rare form of dementia is inherited in an autosomal dominant pattern and is characterized by symptoms such as progressive cognitive decline, hearing loss, cataracts, and cerebellar ataxia. The genetic test plays a crucial role in confirming the diagnosis, enabling early intervention and management strategies for affected individuals and their families.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, usually through a blood draw or a cheek swab. The laboratory then analyzes the sample to identify any mutations in the ITM2B gene that are indicative of Familial Danish Dementia. The process is highly accurate and provides vital information for the genetic counseling of families, helping them understand the risk of inheritance and consider future reproductive choices.
The cost of the ITM2B Gene Dementia Familial Danish Type Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of the information it provides for affected families in terms of planning, management, and support cannot be overstated. Early diagnosis through this test can significantly impact the quality of life of individuals with Familial Danish Dementia and their caregivers by allowing for timely interventions and support systems to be put in place.
The "GRN Gene Dementia Frontotemporal Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the GRN gene, which have been linked to frontotemporal dementia (FTD). Frontotemporal dementia is a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the brain, affecting personality, behavior, and language. Mutations in the GRN gene are known to cause a significant proportion of cases of familial FTD, making this test crucial for individuals with a family history of the disease. By analyzing a person's DNA, the test can detect specific genetic alterations in the GRN gene that are associated with an increased risk of developing FTD. This information can be invaluable for early diagnosis and management of the condition, as well as for informing family members about their potential risk. The test is priced at 4400 AED and is conducted at DNA Labs UAE, a facility renowned for its state-of-the-art genetic testing services.
The MAPT gene dementia frontotemporal genetic test is a specialized diagnostic tool aimed at identifying mutations in the MAPT gene, which have been linked to the development of frontotemporal dementia (FTD). FTD is a type of dementia that primarily affects the frontal and temporal lobes of the brain, leading to changes in personality, behavior, and language. The test is designed to help in the early detection and management of this condition by analyzing the patient's DNA for specific genetic variations associated with the disease.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, this test offers a crucial resource for individuals with a family history of frontotemporal dementia or those exhibiting early symptoms of the disease. By identifying the genetic markers associated with FTD, healthcare providers can better understand the risk, tailor treatment plans, and offer genetic counseling to affected families.
The cost of the MAPT gene dementia frontotemporal genetic test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of the information it provides for affected individuals and their families can be immeasurable, potentially offering insights that enable more personalized and effective management of frontotemporal dementia.
The PSEN1 Gene Dementia Frontotemporal Genetic Test is a specialized diagnostic assessment available at DNA Labs UAE, designed to identify mutations in the PSEN1 gene, which are associated with a higher risk of developing frontotemporal dementia (FTD) and other forms of dementia. This genetic testing is crucial for individuals with a family history of dementia, as it can provide valuable insights into their genetic predisposition to this condition. By analyzing the PSEN1 gene, healthcare professionals can better understand the genetic factors contributing to the development of dementia, enabling early intervention and personalized management plans for those at risk. The test is priced at 4400 AED, reflecting the comprehensive analysis and expert consultation provided by DNA Labs UAE to ensure accurate diagnosis and guidance for individuals and their families.
The TARDBP Gene Dementia Frontotemporal Genetic Test is a specialized diagnostic tool designed to identify mutations in the TARDBP gene, which have been linked to frontotemporal dementia (FTD). This condition is a type of dementia characterized by progressive damage to the frontal and/or temporal lobes of the brain, affecting behavior, language, and emotional control. The test is particularly crucial for individuals with a family history of FTD, as it can provide valuable insights into their genetic predisposition to developing the condition.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test involves analyzing the patient's DNA to detect specific genetic alterations in the TARDBP gene that are associated with the development of frontotemporal dementia. The process is non-invasive, usually requiring only a blood sample or cheek swab from the patient.
The cost of the TARDBP Gene Dementia Frontotemporal Genetic Test is 4400 AED. While the price may seem significant, the test offers crucial information that can aid in early diagnosis, allowing for better management of the condition through tailored treatment plans and lifestyle adjustments. Early diagnosis can also help families prepare for the future and make informed decisions regarding care and support for their loved ones.
In summary, the TARDBP Gene Dementia Frontotemporal Genetic Test at DNA Labs UAE is a valuable diagnostic tool for individuals at risk of developing frontotemporal dementia, providing them with early detection and the opportunity to manage the condition proactively.
The SNCA Gene Dementia Lewy Body Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the SNCA gene, which are associated with an increased risk of developing Lewy body dementia (LBD). Lewy body dementia is a progressive brain disorder characterized by the abnormal accumulation of alpha-synuclein protein in the brain, leading to cognitive decline, movement disorders, and psychiatric symptoms. By analyzing the SNCA gene, this test helps in confirming the diagnosis, understanding the risk, and aiding in the management of the condition for patients and their families. The test is priced at 4400 AED, reflecting the comprehensive analysis and the specialized technology utilized in identifying the genetic variations linked to this form of dementia. Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, the test represents a crucial step forward in the personalized treatment and understanding of Lewy body dementia.
The OCRL Gene Dent Disease Type 2 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the OCRL gene, which are associated with Dent Disease Type 2. This rare genetic disorder is characterized by kidney problems, including excessive excretion of proteins and other substances in the urine, which can lead to kidney failure and other complications. The test is crucial for early detection and management of the condition, providing essential information for healthcare providers to develop an appropriate treatment plan. Priced at 4400 AED, the test represents a significant step towards personalized medicine, enabling targeted interventions that can significantly improve the quality of life for individuals with Dent Disease Type 2.
The ATN1 Gene Dentatorubral-Pallidoluysian Atrophy (DRPLA) Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at detecting mutations in the ATN1 gene, which are responsible for causing Dentatorubral-Pallidoluysian Atrophy. DRPLA is a rare, autosomal dominant neurodegenerative disorder characterized by a wide range of neurological symptoms, including ataxia, choreoathetosis, seizures, and cognitive decline, which tend to worsen over time. The onset of symptoms can vary greatly, appearing in childhood or adulthood, making early and accurate diagnosis crucial for managing the condition.
This genetic test involves analyzing the patient's DNA to identify mutations in the ATN1 gene that indicate the presence of DRPLA. By pinpointing these genetic abnormalities, healthcare providers can confirm a diagnosis of DRPLA, allowing for early intervention, appropriate management strategies, and genetic counseling for affected families. The test cost is set at 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the specific genetic alterations associated with this condition.
Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and commitment to providing accurate, reliable results, the ATN1 Gene DRPLA Genetic Test represents a crucial resource for individuals and families at risk of this challenging disorder, offering hope for better understanding and management of their condition.
